Scarica l'app Stockscreener
123.95
4.70%
5.56
Dopo l'orario di chiusura:
123.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVTY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$118.39
Aprire:
$119.02
Volume 24 ore:
1.21M
Relative Volume:
1.41
Capitalizzazione di mercato:
$15.08B
Reddito:
$2.72B
Utile/perdita netta:
$254.30M
Rapporto P/E:
59.98
EPS:
2.0665
Flusso di cassa netto:
$564.37M
1 W Prestazione:
+2.67%
1M Prestazione:
+10.12%
6M Prestazione:
+14.61%
1 anno Prestazione:
+16.46%
Intervallo 1D:
$118.83
$124.04
Intervallo di 1 settimana:
$116.60
$124.04
Portata 52W:
$97.31
$129.50
Revvity Inc Stock (RVTY) Company Profile
Nome
Revvity Inc
Settore
Industria
Telefono
781-663-6900
Indirizzo
77 4TH AVENUE, WALTHAM
Confronta RVTY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
123.95 | 15.08B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-07-08 | Iniziato | Leerink Partners | Outperform |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-23 | Ripresa | Goldman | Buy |
Mostra tutto
Revvity Inc Borsa (RVTY) Ultime notizie
Raymond James Lowers Revvity (NYSE:RVTY) Price Target to $140.00 - MarketBeat
Revvity Inc (RVTY) Shares Up 3.21% on Jan 21 - GuruFocus.com
Lentiviral Vectors Market Generated Opportunities, Future - openPR
Avanza Fonder AB Invests $898,000 in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Oak Thistle LLC Purchases Shares of 2,842 Revvity, Inc. (NYSE:RVTY) - MarketBeat
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test - MSN
Stocks Showing Improved Relative Strength: Revvity - MSN
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Contravisory Investment Management Inc. - MarketBeat
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and McGrath RentCorp - Nasdaq
Revvity’s Q4 2024 Earnings: What to Expect - Nasdaq
Neurogenomics Market Forecast and Trends Analysis to 2031: Healthcare Investments and Early Detection Drive Robust Uptake of Neurogenomics Solutions - GlobeNewswire Inc.
Revvity’s Q4 2024 Earnings: What To Expect - Barchart
Revvity to Seek M&A -January 13, 2025 at 11:15 am EST - Marketscreener.com
Revvity’s $1.5 Billion Syndicated Revolving Credit Facility - Global Legal Chronicle
Revvity (NYSE:RVTY) Shares Gap UpHere's What Happened - MarketBeat
Revvity to Announce Q4 and Full-Year 2024 Results - TipRanks
Revvity Partners with Element Biosciences to Transform Neonatal Genetic Testing - StockTitan
Revvity Announces FDA Clearance for First Automated Free Testosterone Test - Technology Networks
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance - Business Wire
Revvity wins FDA clearance for ChLIA assay in free testosterone measurement - MSN
Revvity Wins FDA Nod for Automated Free Testosterone Test - MPO-mag
Bernstein revises Revvity stock outlook—can stability outweigh slowing growth? - Investing.com Nigeria
Revvity gets FDA clearance for first automated free testosterone test - MSN
Revvity (NYSE:RVTY) Downgraded by Sanford C. Bernstein to "Market Perform" - MarketBeat
Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone Test -January 10, 2025 at 08:00 am EST - Marketscreener.com
Bernstein revises Revvity stock outlook—can stability outweigh slowing growth? By Investing.com - Investing.com South Africa
RVTYRevvity, Inc. Latest Stock News & Market Updates - StockTitan
Revvity Secures FDA Clearance for First-Ever Automated Free Testosterone Test - StockTitan
Revvity (FRA:PKN) Earnings Yield (Joel Greenblatt) % : 1.99% (As of Sep. 2024) - GuruFocus.com
No time to waste: Revvity CFO Max Krakowiak - CFO.com
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity, Inc. (NYSE:RVTY) Insider Tajinder S. Vohra Sells 5,492 Shares - MarketBeat
Revvity secures new $1.5 billion credit facility By Investing.com - Investing.com Canada
Revvity, Inc. (RVTY) Secures New $1.5 Billion Unsecured Revolvin - GuruFocus.com
Revvity secures new $1.5 billion credit facility - Investing.com
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Shareholders Should Be Pleased With Revvity, Inc.'s (NYSE:RVTY) Price - Simply Wall St
Revvity, Inc. (NYSE:RVTY) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Revvity, Inc. (NYSE:RVTY) Shares Sold by Everence Capital Management Inc. - MarketBeat
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN
Revvity (FRA:PKN) Float Percentage Of Total Shares Outstanding : 75.15% (As of Dec. 30, 2024) - GuruFocus.com
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
(RVTY) Proactive Strategies - Stock Traders Daily
Is Revvity Stock Underperforming the S&P 500? - Nasdaq
Revvity Inc Azioni (RVTY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):